About
NICO Corporation is a medical device company dedicated to transforming minimally invasive neurosurgery through a tightly integrated systems approach. Rather than offering standalone tools, NICO provides a complete solution that unifies imaging and intervention, enabling surgeons to operate with greater precision and minimal disruption to surrounding brain tissue. Their core product, the NICO Myriad, is an FDA-cleared multi-capability device that supports fluorescence-guided surgery via blue excitation light, and is designed for flexible, hand-held use in the operating room. Complementing this is BrainPath, a minimally invasive port system that creates a stable corridor to deep brain targets. NICO's technologies are supported by robust clinical evidence — most notably the ENRICH trial, the first positive randomized controlled trial demonstrating improved functional and economic outcomes for intracerebral hemorrhage (ICH) patients, with results published in The New England Journal of Medicine. The company also invests in neurosurgeon education and training, pre-clinical research support, and global distribution partnerships. NICO Corporation serves neurosurgeons, hospitals, academic medical centers, and healthcare systems seeking to improve patient outcomes while driving surgical efficiency.
Key Features
- NICO Myriad SPECTRA: FDA-cleared, multi-capability handheld device with blue excitation light to support fluorescence-guided neurosurgery.
- BrainPath Port System: Minimally invasive port technology that creates a stable, low-trauma corridor to deep brain targets during surgery.
- Integrated Systems Approach: Combines imaging and surgical intervention into a single cohesive platform, improving workflow efficiency for surgeons and hospitals.
- ENRICH Clinical Trial Evidence: Landmark RCT published in The New England Journal of Medicine showing improved functional and economic outcomes for intracerebral hemorrhage patients.
- Neurosurgeon Education & Training: Dedicated training programs and medical education resources to support adoption of minimally invasive neurosurgical techniques.
Use Cases
- Minimally invasive surgical evacuation of intracerebral hemorrhage (ICH) using the BrainPath port system guided by NICO Myriad imaging.
- Fluorescence-guided neurosurgery using the NICO Myriad SPECTRA's blue excitation light to improve tumor visualization and resection accuracy.
- Pre-clinical neurosurgical research using NICO technologies to develop and validate new minimally invasive surgical techniques.
- Neurosurgeon training programs aimed at reducing the learning curve for minimally invasive brain surgery approaches.
- Hospital and health system adoption of an integrated imaging-and-intervention platform to improve patient outcomes and surgical cost-efficiency.
Pros
- Strong Clinical Evidence: The ENRICH trial — the first positive ICH trial — published in The New England Journal of Medicine provides credible, peer-reviewed validation.
- Complete Integrated Solution: Unlike point solutions, NICO offers a systems approach combining imaging and intervention, reducing workflow fragmentation in the OR.
- FDA-Cleared Devices: All core products carry FDA clearance, giving hospitals and surgeons confidence in regulatory compliance and safety.
Cons
- Highly Specialized Use Case: Products are designed exclusively for neurosurgery, limiting applicability to a narrow segment of the surgical market.
- Enterprise Sales Model: Procurement requires direct engagement with NICO sales representatives, with no self-service or transparent pricing available online.
- Requires Specialized Training: Surgeons must complete dedicated training programs to use BrainPath and Myriad systems effectively, adding adoption lead time.
Frequently Asked Questions
What is the NICO Myriad SPECTRA?
The NICO Myriad SPECTRA is the company's latest FDA-cleared innovation — a handheld, multi-capability device that includes blue excitation light functionality to assist surgeons with fluorescence-guided brain surgery.
What is BrainPath?
BrainPath is a minimally invasive port system that allows neurosurgeons to access deep brain structures through a small, stable corridor, reducing trauma to surrounding healthy tissue.
What was the ENRICH clinical trial?
ENRICH was a randomized controlled trial evaluating NICO's minimally invasive approach to treating intracerebral hemorrhage (ICH). It was the first positive trial to demonstrate improved functional and economic outcomes for ICH patients, with results published in The New England Journal of Medicine.
Who are NICO Corporation's products designed for?
NICO's products are designed for neurosurgeons, hospitals, academic medical centers, and healthcare systems performing brain surgery, particularly for conditions like intracerebral hemorrhage.
Does NICO offer training for surgeons?
Yes, NICO Corporation provides neurosurgeon training and medical education programs to help surgical teams adopt and optimize their minimally invasive neurosurgical technologies.
